==== Front
Case Rep Cardiol
Case Rep Cardiol
CRIC
Case Reports in Cardiology
2090-6404
2090-6412
Hindawi

10.1155/2023/7646962
Case Report
Acute Lymphocytic Myocarditis in a Young Male Post-COVID-19
Bohné Mintje 1
Bohnen Sebastian 1
Willems Stephan 1
Klingel Karin 2
Kivelitz Dietmar 3
https://orcid.org/0000-0002-5360-783X
Bahlmann Edda e.bahlmann@asklepios.com
1
1Department of Cardiology, Asklepios Clinic St. Georg, Hamburg, Germany
2Cardiopathology, Institute for Pathology, University Hospital Tübingen, Tübingen, Germany
3Department of Radiology, Asklepios Clinic St. Georg, Hamburg, Semmelweis University, Budapest, Asklepios CampusHamburg, Germany
Academic Editor: Manabu Shirotani

2023
22 6 2023
2023 764696227 12 2022
10 3 2023
1 6 2023
Copyright © 2023 Mintje Bohné et al.
2023
https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Background

Lymphocytic myocarditis is a rare form of myocarditis, associated with a high mortality rate due to a high risk of sudden cardiac death. Lymphocytic myocarditis might present as a relevant extrapulmonary manifestation after coronavirus disease 2019 (COVID-19) infection. Case presentation. We report a case of a 26-year-old male with lymphocytic myocarditis, presenting with a 1-month history of increasing fatigue, palpitations, and shortness of breath. Eight weeks before, he was tested positive for SARS-CoV-2. He had received 2-dose schedule of the COVID-19 mRNA vaccine Comirnaty® (BioNTech/Pfizer) 6 months prior to his admission. Diagnostic work-up by echocardiography and cardiac magnetic resonance (CMR) imaging demonstrated a severely reduced left ventricular function and a strong midmyocardial late gadolinium enhancement (LGE). Histology and immunohistology of the endomyocardial biopsies revealed an acute lymphocytic myocarditis. Immunosuppressive therapy with a steroid taper in combination with azathioprine 300 mg/day was initiated. The patient was equipped with a LifeVest®. On day 17, a non-sustained ventricular tachycardia was documented. Follow-up CMR imaging after 3 months showed a slightly improved systolic left ventricular function, and a strong LGE was still detectable.

Conclusions

The case highlights the significance of recognizing lymphocytic myocarditis correlated to COVID-19. It is important to be vigilant also of a later presentation of cardiomyopathy in patients diagnosed with COVID-19 due to high mortality without immediate support.
==== Body
pmc1. Background

Myocarditis is an inflammatory disease of the heart muscle with myocyte degeneration and necrosis of non-ischemic origin, which is diagnosed by established histological [1] and immunohistological criteria [2]. The inflammation of the heart may be caused by different infectious agents, systemic diseases, drugs, and toxins, but viral infections are recognized as the most common [2].

2. Case Presentation

2.1. Timeline

We report a 26-year-old, previously healthy male admitted to our emergency unit by his family doctor with a 1-month history of increasing fatigue, palpitations, and shortness of breath. The patient had prior coronavirus disease 2019 (COVID-19) 2 months before his admission. He had received a 2-dose schedule of the COVID-19 mRNA vaccine Comirnaty® (BioNTech/Pfizer) latest 6 months ago. Two weeks prior to his admission, a pulmonary embolism could be ruled out by a thoracic computed tomography scan but was noticeable for a cardiomegaly, residual pulmonary infiltrates, and increased bihilar lymphatic tissue. Physical examination, besides an increased respiratory rate of 17/minute and a heart rate of 123 bpm, revealed no pathologies, in particular no peripheral leg edema. The arterial blood pressure was 124/84 mmHg. Blood analysis was noticeable for elevated cardiac markers with a Troponin I of 103 ng/l (ref: <34 ng/l), D-Dimer of 1.3 mg/l (ref: <0.5 mg/l), and an N-terminal prohormone of brain natriuretic peptide of 2421 ng/l (ref: <125 ng/l). His blood count showed normal hemoglobin concentration, eosinophilic and platelet count, and no leukocytosis. A first nasopharyngeal swab for SARS-CoV-2 RNA detection was negative. Electrocardiogram showed an atrial tachycardia and a right bundle branch block (Figure 1). Transthoracic echocardiogram demonstrated a severely impaired biventricular systolic function. Pericardial effusion could be ruled out as well as a valvular heart disease (Figure 2). After excluding intraventricular thrombus formations, electric cardioversion could restore sinus rhythm, and antiarrhythmic medication with Amiodarone was initiated. Coronary artery disease could be excluded by a coronary angiography, and subsequent left ventricle (LV) endomyocardial biopsies (EMBs) were performed. A guideline-directed heart failure therapy, including Dapagliflozin, Sacubitril/Valsartan, Eplerenone, and beta-blockade, was initiated. Further diagnostic work-up by cardiac magnetic resonance (CMR) imaging on day 8 after admission confirmed a severely reduced LV systolic function with an estimated ejection fraction of 18%, hypokinesia inferoseptal and mediobasal, and a mild LV hypertrophy with an intraventricular septal thickness of 14 mm. Stroke volume index was estimated with 25 ml/m2. CMR showed patchy subepicardial to transmural late gadolinium enhancement (LGE) anteroseptal, inferior, and inferolateral. Global native T1 and T2 were elevated with a nT1 of 1326 ms and a T2 of 60 ms (reference values: nT1 = 1256 (1240–1280) ms and nT2 = 45 (44–47) ms). LGE was evident also in the right ventricular wall. Additionally, enlarged mediastinal and hilar lymph nodes could be detected and a minimal left sided pericardial effusion (Figures 3(a), 3(b), 3(c), and 3(d)). Histology and immunohistology of the EMB revealed an acute lymphocytic myocarditis with focal myocyte necrosis and infiltration of CD3+ T cells and CD68+ macrophages on day 13 (Figures 4(a), 4(b), and 4(c)). Reverse transcription polymerase chain reaction (RT-PCR) for common cardiotropic viruses or bacteria was negative. Moreover, qRT-PCR analyses of the endomyocardial specimen for COVID-19 were negative. Thus, in absence of infectious agents in the myocardium, an immunosuppressive therapy was initiated on day 14 with prednisolone (1 mg/kg/day) and continued for 2 weeks, followed by a dose tapering regimen of 10 mg every 4 weeks in combination with azathioprine 300 mg/day. Due to a significant QTc interval prolongation, Amiodarone had to be terminated, and the patient was equipped with a LifeVest®. On day 17, a non-sustained ventricular tachycardia was documented (Figure 5). Heart failure therapy achieved remission of symptoms, and the patient could be discharged 18 days after admission. He was advised to refrain from high-intense physical activity. Follow-up CMR imaging, scheduled 3 months after hospital discharge, could demonstrate an improved LV systolic function with an estimated LV ejection fraction of 36% and a stroke volume index of 45 ml/m2. While native T1 and T2 normalized, strong LGE was still detectable. Combined immunosuppressive therapy with prednisolone in a dose tapering regimen in combination with azathioprine 300 mg/day was suggested to continue for 6 months.

3. Discussion and Conclusions

In this work, we present a unique case of acute lymphocytic myocarditis in a young man post-COVID-19. An association between a SARS-CoV-2 infection and myocardial injury has been suggested since the outbreak of COVID-19 [3]. The frequency and prognostic impact of COVID-19-mediated myocarditis are unknown [4]. In 2020, SARS-CoV-2 virions were detected in myocytes of infected patients revealing myocarditis [5]. Until 2021, a total of 38 cases (26 male, 24 aged <50 years) of myocarditis in confirmed COVID-19 patients were reviewed [4]. In this report, five patients died in hospital, and the first case was a virus-negative lymphocytic myocarditis, but myocarditis secondary to SARS-CoV-2 cardiotropism has also been demonstrated in EMB [4]. In an autopsy study of eight patients with severe COVID-19, active lymphocytic myocarditis was histologically found in all cases, although myocarditis was not clinically diagnosed [6]. In a clinical study from Wuhan by January 2020, myocardial damage was diagnosed in 12% among 41 admitted hospital patients (30 male) with confirmed COVID-19 [7]. Typical new onset of heart failure symptoms leading to admission in our patient in combination with elevated troponin level and severely reduced LV ejection fraction were suspicious for myocarditis in a young man [8, 9]. The definite diagnosis of lymphocytic myocarditis was established in EMB and underlines the recommended concept of EMB as gold standard in patients with clinically suspected myocarditis [10]. Lymphocytic myocarditis as presented here, however, could have a long list of potential causes, mainly virus-induced, by direct virus-mediated or indirect immune-mediated myocardial injury [11]. Persistence of the virus in EMB was associated with worse outcomes compared to viral clearance [12]. Of note, parvovirus B19 appears to cause both virus-mediated and virus-triggered myocarditis, whereas respiratory viruses, such as influenza and coronaviruses, can trigger an immune-mediated lymphocytic myocarditis in the absence of viral genome in the myocardium [13, 14]. However, cause–effect relationship between SARS-CoV-2 infection and myocarditis is difficult to demonstrate [4]. In our case, describing a young patient, recently going through COVID-19, we could not detect SARS-CoV-2 RNA by RT-PCR in EMB. This might, as discussed in a report of 18 patients with COVID-19 and myocardial injury, be explained by transient viral infection or due to immunologic effects causing myocardial inflammation without direct viral infection of cardiomyocytes [4, 15]. It is not uncommon that the underlying organism in lymphocytic myocarditis is not detected as it is often cleared by the immune system before significant inflammation occurs [2, 16]. In viral myocarditis, follow-up analysis of EMBs by PCR documented spontaneous clearance of viral genomes in 36.2% [12].

Acute myocarditis following mRNA COVID-19 vaccination is reported by the European Medicine Agency safety committee as a rare adverse event [17]. Also, according to the US Centers for Disease Control and Prevention, myocarditis/pericarditis rates are described with 13 cases per million doses of second-dose mRNA vaccine [18]. In multiple studies/case reports describing acute myocarditis following COVID-19 mRNA vaccines, however, this adverse event usually occurs shortly after the second dose [8, 19–21]. The patients presented with chest pain had elevated cardiac troponin levels, an abnormal ECG with ST elevations in most, and CMR imaging was suggestive of myocarditis in all and none of the patients had evidence of acute COVID-19 [21–23]. Typically, these patients are younger aged male and most required hospitalization up to 4 days but were considered mild [24]. Most cases recovered completely with or without heart failure treatment within 1 month [19, 21, 24–26]. Most recently it was shown that, especially in young men, IL-1RA antibodies are relevant in the pathogenesis of myocarditis after SARS-CoV-2 mRNA vaccination [27]. Despite rare cases of myocarditis, the benefit–risk assessment for COVID-19 vaccination showed a favorable balance for all age and sex groups [21].

As clinical condition was sufficiently stable in our patient, heart failure medication was initiated immediately [28]. The beneficial effect of immunosuppressive therapy in biopsy-proven virus-negative lymphocytic myocarditis could be demonstrated in the randomized, double-blind, placebo-controlled Tailored IMmunosuppression in virus-negative Inflammatory Cardiomyopathy (TIMIC) trial including 85 patients [29]. In this trial, the patients received prednisone and azathioprine (n = 43) vs. placebo (n = 42) for 6 months [29]. The benefit from immunosuppressive therapy could recently be demonstrated also after long-term follow-up (up to 20 years) [30]. The risk of cardiovascular death and heart transplantation was significantly lower in treated patients included in the TIMIC trial, and patients showed persistent improvement in the LV ejection fraction compared with the placebo group [30]. Long-term benefit of combined immunosuppressive therapy, including steroids and azathioprine, could also be shown in dilated cardiomyopathy [31]. Early and late favorable effects of immunosuppressive therapy could particularly been shown for improvement of LV function, although improvement was also shown in the placebo group, but less often [31]. In our patient, however, we thought improvement of LV function was most probably related to immunosuppressive therapy. Until now, limited data support the use of immunosuppressive agents in COVID-19-associated cardiac involvement [32]. In acute myocarditis, as in our case, polymorphic and irregular ventricular arrhythmias are particularly common and present a relevant risk [33]. As a consequence, a LifeVest®, as wearable cardioverter defibrillator for primary prevention of sudden cardiac, was implanted due to the high risk of sudden cardiac death in our patient. While the patient has improved LV ejection fraction >35%, was asymptomatic with remission of symptoms, NYHA I, and had no history of cardiac arrest or sustained ventricular tachycardia, no permanent cardioverter defibrillator was implanted. He had clearly a lowered risk due to heart failure therapy, and the European Society of Cardiology guidelines recommend an cardioverter defibrillator in either secondary prevention or symptomatic patients (NYHA II–III) with an LV ejection fraction ≤35% [33]. Physical activity should be restricted during the acute phase of myocarditis until the disease has completely resolved as recommended in our case [34].

4. Conclusion

The case presented highlights the importance of awareness for an extrapulmonary manifestation after COVID-19 involving the heart. There is need for evaluation of therapeutic approaches in acute lymphocytic myocarditis related to COVID-19 to facilitate the development of personalized treatment options.

Abbreviations

EMB: Endomyocardial biopsy

LV: Left ventricle

COVID-19: Coronavirus disease 2019

CMR: Cardiac magnetic resonance

LGE: Late gadolinium enhancement.

Data Availability

Data and material are presented within the manuscript.

Consent

Written consent was obtained from the patient for publication of this case report. I confirm that a copy of the consent form is available for review by the editor upon request.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors' Contributions

MB, SB, SW, and EB were responsible for the patient care and data collection. SB analyzed the data from cardiac magnetic resonance. All authors provided comments on the report at various stages of development. All authors read and approved the final manuscript.

Figure 1 Electrocardiogram demonstrating atrial tachycardia with 127 beats per minute and a right bundle branch block configuration.

Figure 2 Transthoracic echocardiography showing four chamber cardiac view.

Figure 3 CMR imaging study showing severe LV dysfunction and signs of acute myocarditis. (a and c) Three-chamber views, (b and d) short axis views. (a and b) LGE images with severe subepicardial to transmural LGE inferolateral and anterolateral. (c and d) Native T1-maps with focal increased native T1 values in LGE positive regions.

Figure 4 Histopathological images. (a) Histological findings in the endomyocardial biopsy showing active lymphocytic myocarditis with necrosis and areas of organization (Giemsa), (b) CD3 and T-cells, and (c) CD 68 and macrophages.

Figure 5 Electrocardiogram demonstrating non-sustained ventricular tachycardia and frequent premature ventricular complexes.

Table 1 Time	Events	
Day 1	1-month history of increasing fatigue, palpitations, and shortness of breath	
12-lead electrocardiogram showed an atrial tachycardia with 127 bpm. Transthoracic echocardiogram showed a severely impaired biventricular systolic function with an estimated left ventricular ejection fraction of 18%. After excluding intraventricular thrombus formations, electric cardioversion could restore sinus rhythm.	
Day 2	Coronary angiography showed normal coronary arteries. Left ventricular endomyocardial biopsy was performed.	
Day 2	Transfer to intermediate care unit and optimization of medical heart failure therapy.	
Day 8	Cardiac magnetic resonance imaging confirmed a severely reduced left ventricular function. Increased signaling of the interventricular myocardium and strong midmyocardial late gadolinium enhancement (LGE) was noticeable. LGE was evident also in the right ventricle.	
Day 13	Histology and immunohistology of the endomyocardial biopsies revealed an acute lymphocytic myocarditis. RT-PCR revealed no infection with common cardiotropic viruses. Immunosuppressive therapy with prednisolone was initiated (1 mg/kg/day) in combination with azathioprine 300 mg/day.	
Day 15	Patient was equipped with a LifeVest®.	
Day 17	Documentation of a non-sustained ventricular tachycardia.	
Day 20	Patient was discharged on a steroid taper in combination with azathioprine 300 mg/day.	
Follow-up at 3 months	Follow-up cardiac magnetic resonance imaging was performed on an outpatient basis. An improved LV systolic function with an estimated LV ejection fraction of 36% was evident, and a strong LGE was still detectable.
==== Refs
1 Aretz H. T. Myocarditis: the Dallas criteria Human Pathology 1987 18 6 619 624 10.1016/S0046-8177(87)80363-5 2-s2.0-0023181940 3297992
2 Caforio A. L. P. Pankuweit S. Arbustini E. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on myocardial and pericardial diseases European Heart Journal 2013 34 33 2636 2648 10.1093/eurheartj/eht210 2-s2.0-84883746417 23824828
3 He X. W. Lai J. S. Cheng J. Impact of complicated myocardial injury on the clinical outcome of severe or critically ill COVID-19 patients Za Zhi 2020 48 456 460
4 Castiello T. Georgiopoulos G. Finocchiaro G. COVID-19 and myocarditis: a systematic review and overview of current challenges Heart Failure Reviews 2022 27 1 251 261 10.1007/s10741-021-10087-9 33761041
5 Bojkova D. Wagner J. U. G. Shumliakivska M. SARS-CoV-2 infects and induces cytotoxic effects in human cardiomyocytes Cardiovascular Research 2020 116 14 2207 2215 10.1093/cvr/cvaa267 32966582
6 Kogan E. Berezovskiy Y. Blagova O. Morphologically, immunohistochemically and PCR proven lymphocytic viral peri-, endo-, myocarditis in patients with fatal COVID-19 Diagnostic Pathology 2022 17 1 p. 31 10.1186/s13000-022-01207-6
7 Huang C. Wang Y. Li X. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China Lancet 2020 395 10223 497 506 10.1016/S0140-6736(20)30183-5 31986264
8 Gargano J. W. Wallace M. Hadler S. C. Use of mRNA COVID-19 vaccine after reports of myocarditis among vaccine recipients: update from the Advisory Committee on Immunization Practices—United States, June 2021 MMWR. Morbidity and Mortality Weekly Report 2021 70 27 977 982 10.15585/mmwr.mm7027e2 34237049
9 Trachtenberg B. H. Hare J. M. Inflammatory cardiomyopathic syndromes Circulation Research 2017 121 7 803 818 10.1161/CIRCRESAHA.117.310221 2-s2.0-85030610110 28912184
10 Kindermann I. Barth C. Mahfoud F. Update on myocarditis Journal of the American College of Cardiology 2012 59 9 779 792 10.1016/j.jacc.2011.09.074 2-s2.0-84857308128 22361396
11 Ammirati E. Frigerio M. Adler E. D. Management of acute myocarditis and chronic inflammatory cardiomyopathy Circulation. Heart Failure 2020 13 11, article e007405 10.1161/CIRCHEARTFAILURE.120.007405 33176455
12 Kühl U. Pauschinger M. Seeberg B. Viral persistence in the myocardium is associated with progressive cardiac dysfunction Circulation 2005 112 13 1965 1970 10.1161/CIRCULATIONAHA.105.548156 2-s2.0-25444453550 16172268
13 Bratincsák A. El-Said H. G. Bradley J. S. Shayan K. Grossfeld P. D. Cannavino C. R. Fulminant myocarditis associated with pandemic H1N1 influenza a virus in children Journal of the American College of Cardiology 2010 55 9 928 929 10.1016/j.jacc.2010.01.004 2-s2.0-76849092337 20153131
14 Veronese G. Cipriani M. Bottiroli M. Fulminant myocarditis triggered by OC43 subtype coronavirus: a disease deserving evidence-based care bundles Journal of Cardiovascular Medicine 2020 21 7 529 531 10.2459/JCM.0000000000000989 32487867
15 Weckbach L. T. Curta A. Bieber S. Myocardial inflammation and dysfunction in COVID-19–associated myocardial injury Circulation. Cardiovascular Imaging 2021 14 1, article e011713 10.1161/CIRCIMAGING.120.011713
16 Blagova O. Nedostup A. Kogan E. Zaitsev A. Fomin V. Immunosuppressive therapy of biopsy proved immune-mediated lymphocytic myocarditis in the virus-negative and virus-positive patients Cardiovascular Pathology 2020 49 p. 107260 10.1016/j.carpath.2020.107260 32683240
17 European Medicine Agency Comirnaty and Spikevax: possible link to very rare cases of myocarditis and pericarditis. https://wwwemaeuropaeu/en/news/comirnaty-spikevax-possible-link-very-rare-cases-myocarditis-pericarditis. 2021
18 Centers for Disease Control and Prevention (CDC). Advisory Committee on Immunization Practices (ACIP). Coronavirus disease 2019 (COVID-19) vaccines. Accessed July 6. https://www.cdc.gov/vaccines/acip/meetings/slides-2021-06.html
19 Kiblboeck D. Klingel K. Genger M. Myocarditis following mRNA COVID-19 vaccination: call for endomyocardial biopsy ESC Heart Failure 2022 9 3 1996 2002 10.1002/ehf2.13791 35194974
20 Horiuchi K. Kosugi S. Abe H. Ueda Y. Fulminant myocarditis after the first dose of mRNA-1273 vaccination in a patient with previous COVID-19: a case report European Heart Journal. Case Reports 2022 6 7 1 5 10.1093/ehjcr/ytac290
21 Bozkurt B. Kamat I. Hotez P. J. Myocarditis with COVID-19 mRNA vaccines Circulation 2021 144 6 471 484 10.1161/CIRCULATIONAHA.121.056135 34281357
22 Rosner C. M. Genovese L. Tehrani B. N. Myocarditis temporally associated with COVID-19 vaccination Circulation 2021 144 6 502 505 10.1161/CIRCULATIONAHA.121.055891 34133885
23 Larson K. F. Ammirati E. Adler E. D. Myocarditis after BNT162b2 and mRNA-1273 vaccination Circulation 2021 144 6 506 508 10.1161/CIRCULATIONAHA.121.055913 34133884
24 Israel Ministry of Health. Surveillance of myocarditis (inflammation of the heart muscle) cases between December 2020 and May 2021 (including). June 2 AJ, 2021. https://www.gov.il/en/departments/news/01062021-03
25 Atkins M. Bakhshi H. Chaudhri S. Myocarditis temporally associated with COVID-19 vaccination Circulation 2021 144 6 502 505 10.1161/CIRCULATIONAHA.121.055891 34133885
26 Abu Mouch S. Roguin A. Hellou A. Myocarditis following COVID-19 mRNA vaccination Vaccine 2021 39 29 3790 3793 10.1016/j.vaccine.2021.05.087 34092429
27 Thurner L. Kessel C. Fadle N. IL-1RA antibodies in myocarditis after SARS-CoV-2 vaccination The New England Journal of Medicine 2022 387 16 1524 1527 10.1056/NEJMc2205667 36130012
28 Merlo M. Ammirati E. Gentile P. Persistent left ventricular dysfunction after acute lymphocytic myocarditis: frequency and predictors PLoS One 2019 14 3, article e0214616 10.1371/journal.pone.0214616 2-s2.0-85063609371
29 Frustaci A. R. M. Chimenti C. Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC study European Heart Journal 2009 30 16 1995 2002 10.1093/eurheartj/ehp249 2-s2.0-68949154620 19556262
30 Chimenti C. Russo M. A. Frustaci A. Immunosuppressive therapy in virus-negative inflammatory cardiomyopathy: 20-year follow-up of the TIMIC trial European Heart Journal 2022 43 36 3463 3473 10.1093/eurheartj/ehac348 35831932
31 Wojnicz R. Nowalany-Kozielska E. Wojciechowska C. Randomized, placebo-controlled study for immunosuppressive treatment of inflammatory dilated cardiomyopathy Circulation 2001 104 1 39 45 10.1161/01.CIR.104.1.39 2-s2.0-0035800063 11435335
32 Hu H. Ma F. Wei X. Fang Y. Coronavirus fulminant myocarditis saved with glucocorticoid and human immunoglobulin European Heart Journal 2021 42 2 p. 191 10.1093/eurheartj/ehaa190
33 McDonagh T. A. Metra M. Adamo M. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) European Heart Journal 2021 42 36 3599 3726 10.1093/eurheartj/ehab368 34447992
34 Pelliccia A. Sharma S. Gati S. 2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease European Heart Journal 2021 42 1 17 96 10.1093/eurheartj/ehaa605 32860412